NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. TRIPACEL® …
View More Tripacel
Home » Medications »
Abyraz
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. ABYRAZ aripiprazole…
View More Abyraz
FDA Approves Cabenuva and Vocabria
FDA Approves Cabenuva (cabotegravir and rilpivirine) Long-Acting Injectable HIV Treatment and Vocabria (cabotegravir) Oral HIV…
View More FDA Approves Cabenuva and Vocabria
Florida Fails to Attract Bidders for Canada Drug Importation Program
Florida’s plan to import cheaper prescription drugs from Canada — designed by Gov. Ron DeSantis…
View More Florida Fails to Attract Bidders for Canada Drug Importation Program
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
HOUSTON, Dec. 1, 2020 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a…
View More Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 29, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics…
View More Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
TARRYTOWN, N.Y., Oct. 30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2…
View More REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus)
TARRYTOWN, N.Y., Oct. 14, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that…
View More FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus)
Vir Biotechnology and GSK Announce Global Expansion to Phase 3 of COMET-ICE Study Evaluating VIR-7831 for the Treatment of COVID-19
06 October 2020 — Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today…
View More Vir Biotechnology and GSK Announce Global Expansion to Phase 3 of COMET-ICE Study Evaluating VIR-7831 for the Treatment of COVID-19
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that…
View More FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma